Background: β-Synuclein (β-Syn) is a member of the highly homologous synuclein protein family. The most prominent family member, α-synuclein (α-Syn), abnormally accumulates in so-called Lewy bodies, one of the major pathological hallmarks of α-synucleinopathies. Notably, parts of the peptide backbone, called the nonamyloid component, are also found in amyloid plaques. However, β-Syn seems to have beneficial effects by reducing α-Syn aggregation, and amyloid antiaggregatory activity has been described. Objective: The aim of the study was to analyze if wild-type β-Syn can counteract functional and pathological changes in a murine Alzheimer model over different time periods. Methods: At the onset of pathology, lentiviral particles expressing human β-Syn were injected into the hippocampus of transgenic mice overexpressing human amyloid precursor protein with Swedish and London mutations (APPSL). An empty vector served as the control. Behavioral analyses were performed 1, 3 and 6 months after injection followed by biochemical and histological examinations of brain samples. Results: β-Syn expression was locally concentrated and rather modest, but nevertheless changed its effect on APP expression and plaque load in a time- and concentration-dependent manner. Interestingly, the phosphorylation of glycogen synthase kinase 3 beta was enhanced in APPSL mice expressing human β-Syn, but an inverse trend was observed in wild-type animals. Conclusion: The initially reported beneficial effects of β-Syn could be partially reproduced, but locally elevated levels of β-Syn might also cause neurodegeneration. To enlighten the controversial pathological mechanism of β-Syn, further examinations considering the relationship between concentration and exposure time of β-Syn are needed.

1.
Crews L, Tsigelny I, Hashimoto M, Masliah E: Role of synucleins in Alzheimer's disease. Neurotox Res 2009;16:306-317.
2.
Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, Lesné SE: Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci 2012;32:10253-10266.
3.
Ulusoy A, Di Monte D: Α-synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mol Neurobiol 2013;47:484-494.
4.
George J: The synucleins. Genome Biol 2001;3:reviews3002.3001-reviews3002.3006.
5.
Oaks AW, Sidhu A: Synuclein modulation of monoamine transporters. FEBS Lett 2011;585:1001-1006.
6.
Oaks AW, Marsh-Armstrong N, Jones JM, Credle JJ, Sidhu A: Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS One 2013;8:e70872.
7.
Chandra S, Fornai F, Kwon H-B, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Südhof TC: Double-knockout mice for α- and β-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 2004;101:14966-14971.
8.
Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM, Nie EH, Makani S, Tian N, Castillo PE, Buchman VL, Chandra SS: αβγ-synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci USA 2010;107:19573-19578.
9.
Anwar S, Peters O, Millership S, Ninkina N, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, Buchman VL: Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci 2011;31:7264-7274.
10.
Lavedan C, Leroy E, Torres R, Dehejia A, Dutra A, Buchholtz S, Nussbaum RL, Polymeropoulos MH: Genomic organization and expression of the human β-synuclein gene (SNCB). Genomics 1998;54:173-175.
11.
Jensen PH, Sørensen ES, Petersen TE, Gliemann J, Rasmussen LK: Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. Biochem J 1995;310:91-94.
12.
Davidson WS, Jonas A, Clayton DF, George JM: Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998;273:9443-9449.
13.
Eliezer D, Kutluay E, Bussell R Jr, Browne G: Conformational properties of α-synuclein in its free and lipid-associated states. J Mol Biol 2001;307:1061-1073.
14.
Bertoncini CW, Rasia RM, Lamberto GR, Binolfi A, Zweckstetter M, Griesinger C, Fernandez CO: Structural characterization of the intrinsically unfolded protein β-synuclein, a natural negative regulator of α-synuclein aggregation. J Mol Biol 2007;372:708-722.
15.
Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
16.
Uversky VN: Α-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci 2008;9:507-540.
17.
Uéda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T: Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90:11282-11286.
18.
Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, Rohan de Silva HA, Kittel A, Saitoh T: The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-475.
19.
Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, Gliemann J, Jakes R: Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J 1997;323:539-546.
20.
Park JY, Lansbury PT Jr: β-Synuclein inhibits formation of α-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 2003;42:3696-3700.
21.
Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E: β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001;32:213-223.
22.
Shaltiel-Karyo R, Frenkel-Pinter M, Egoz-Matia N, Frydman-Marom A, Shalev DE, Segal D, Gazit E: Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS One 2010;5:e13863.
23.
Kessler JC, Rochet J-C, Lansbury PT: The N-terminal repeat domain of α-synuclein inhibits β-sheet and amyloid fibril formation. Biochemistry 2002;42:672-678.
24.
Lee D, Paik SR, Choi KY: Βeta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein. FEBS Lett 2004;576:256-260.
25.
Tabaton M, Zhu X, Perry G, Smith MA, Giliberto L: Signaling effect of amyloid-β42 on the processing of AβPP. Exp Neurol 2010;221:18-25.
26.
Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu G-M, Louis J-C, Martin F, Narhi LO, Citron M: Parkinson's disease-associated α-synuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs. J Biol Chem 2000;275:34574-34579.
27.
Jakes R, Spillantini MG, Goedert M: Identification of two distinct synucleins from human brain. FEBS Lett 1994;345:27-32.
28.
Seo J-H, Rah J-C, Choi SH, Shin JK, Min K, Kim H-S, Park CH, Kim S, Kim E-M, Lee S-H, Lee S, Suh SW, Suh Y-H: α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J 2002;16:1826-1828.
29.
Thomas B, Mandir AS, West N, Liu Y, Andrabi SA, Stirling W, Dawson VL, Dawson TM, Lee MK: Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation. PLoS One 2011;6:e16706.
30.
Hashimoto M, Bar-on P, Ho G, Takenouchi T, Rockenstein E, Crews L, Masliah E: Βeta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J Biol Chem 2004;279:23622-23629.
31.
da Costa CA, Masliah E, Checler F: Βeta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with α-synuclein and implication for Parkinsonʼs disease. J Biol Chem 2003;278:37330-37335.
32.
Windisch M, Hutter-Paier B, Schreiner E: Current drugs and future hopes in the treatment of Alzheimer's disease; in Jellinger K, Schmidt R, Windisch M (eds): Ageing and Dementia: Current and Future Concepts. Vienna, Springer, 2002, vol 62, pp 149-164.
33.
Masliah E, Hansen LA, Rockenstein E, Hashimoto M: Progress in the development of new treatments for combined Alzheimer's and Parkinson's diseases. Drug Dev Res 2002;56:282-292.
34.
Fan Y, Limprasert P, Murray IVJ, Smith AC, Lee VM-Y, Trojanowski JQ, Sopher BL, La Spada AR: Βeta-synuclein modulates α-synuclein neurotoxicity by reducing α-synuclein protein expression. Hum Mol Genet 2006;15:3002-3011.
35.
Hashimoto M, Rockenstein E, Mante M, Crews L, Bar-On P, Gage FH, Marr R, Masliah E: An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 2004;11:1713-1723.
36.
Windisch M, Hutter-Paier B, Schreiner E, Wronski R: Βeta-synuclein-derived peptides with neuroprotective activity. J Mol Neurosci 2004;24:155-165.
37.
Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R: Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? Curr Alzheimer Res 2007;4:446-457.
38.
Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E: Early formation of mature amyloid-β protein deposits in a mutant APP transgenic model depends on levels of Aβ1-42. J Neurosci Res 2001;66:573-582.
39.
Havas D, Hutter-Paier B, Ubhi K, Rockenstein E, Crailsheim K, Masliah E, Windisch M: A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2011;25:231-243.
40.
Mu Y, Gage FH: Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener 2011;6:85.
41.
Kutner RH, Zhang X-Y, Reiser J: Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009;4:495-505.
42.
Athos J, Storm DR: High precision stereotaxic surgery in mice. Curr Protoc Neurosci 2001;Appendix 4:Appendix 4A.
43.
Walf AA, Frye CA: The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007;2:322-328.
44.
Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47-60.
45.
Löffler T, Flunkert S, Havas D, Sántha M, Hutter-Paier B, Steyrer E, Windisch M: Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice. Neurobiol Aging 2013;34:2379-2388.
46.
Löffler T, Flunkert S, Havas D, Schweinzer C, Uger M, Windisch M, Steyrer E, Hutter-Paier B: Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease. J Neuroinflamm 2014;11:84.
47.
Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden T: Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012;13:134.
48.
Haugabook SJ, Yager DM, Eckman EA, Golde TE, Younkin SG, Eckman CB: High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid β peptide (Aβ). J Neurosci Methods 2001;108:171-179.
49.
Czvitkovich S, Duller S, Mathiesen E, Lorenzoni K, Imbimbo B, Hutter-Paier B, Windisch M, Wronski R: Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line. J Mol Neurosci 2011;43:257-267.
50.
Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E: Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 2001;914:48-56.
51.
Beyer K, Domingo-Sàbat M, Santos C, Tolosa E, Ferrer I, Ariza A: The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain 2010;133:3724-3733.
52.
Zhang L, Yu S, Zhang R, Xing Y, Li Y, Li L: Tetrahydroxystilbene glucoside antagonizes age-related α-synuclein overexpression in the hippocampus of APP transgenic mouse model of Alzheimer's disease. Restor Neurol Neurosci 2013;31:41-52.
53.
Taschenberger G, Toloe J, Tereshchenko J, Akerboom J, Wales P, Benz R, Becker S, Outeiro TF, Looger LL, Bähr M, Zweckstetter M, Kügler S: β-Synuclein aggregates and induces neurodegeneration in dopaminergic neurons. Ann Neurol 2013;74:109-118.
54.
Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, Bonner LT, Tsuang DW, Murray IV, Lee VM, Trojanowski JQ, Ishikawa A, Idezuka J, Murata M, Toda T, Bird TD, Leverenz JB, Tsuji S, La Spada AR: Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004;63:805-811.
55.
Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui T, Nakai M, Waragai M, Takenouchi T, Takamatsu Y, Wei J, Rockenstein E, La Spada AR, Masliah E, Inoue S, Hashimoto M: A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun 2010;1:110.
56.
Kao AW, Racine CA, Quitania LC, Kramer JH, Christine CW, Miller BL: Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord 2009;23:365-370.
57.
Marxreiter F, Ettle B, May VEL, Esmer H, Patrick C, Kragh CL, Klucken J, Winner B, Riess O, Winkler J, Masliah E, Nuber S: Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiol Dis 2013;59:38-51.
58.
Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927.
59.
DaRocha-Souto B, Coma M, Pérez-Nievas BG, Scotton TC, Siao M, Sánchez-Ferrer P, Hashimoto T, Fan Z, Hudry E, Barroeta I, Serenó L, Rodríguez M, Sánchez MB, Hyman BT, Gómez-Isla T: Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis 2012;45:425-437.
60.
Hurtado DE, Molina-Porcel L, Carroll JC, MacDonald C, Aboagye AK, Trojanowski JQ, Lee VM: Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 2012;32:7392-7402.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.